JPMorgan analyst Lisa Gill lowered the firm’s price target on GoodRx (GDRX) to $5 from $6 and keeps an Overweight rating on the shares. The firm updated the company’s model.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx price target lowered to $6 from $7 at TD Cowen
- Trump Weekly: China to suspend some controls on rare earths
- Trump Trade: Nvidia says no active talks on selling Blackwell chip to China
- GoodRx will not partner with TrumpRx, CBS News reports
- GoodRx Holdings: Balancing Challenges and Opportunities Amidst PTR Growth Concerns and Pharma Manufacturing Strength